BusheCJTaylorMHaukkaJ (2010) Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol24(4 Suppl): 17–25.
2.
De HertMCorrellCUCohenD (2010) Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res117: 68–74.
3.
DeanCEThurasPD (2009) Mortality and tardive dyskinesia: long-term study using the US National Death Index. Br J Psychiatry194: 360–364.
4.
EngerCWeatherbyLReynoldsRFGlasserDBWalkerAM (2004) Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis192: 19–27.
5.
HasnainMViewegWVFredricksonSKBeatty-BrooksMFernandezAPandurangiAK (2009) Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications. Prim Care Diabetes3: 5–15.
6.
KellyDLMcMahonRPLiuF (2010) Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry71: 304–311.
7.
OsbornDPLevyGNazarethIPetersenIIslamAKingMB (2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry64: 242–249.
8.
TiihonenJLonnqvistJWahlbeckK (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet374: 620–627.
